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Abstract
Endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) have recently been ac-
cepted as less invasive methods for treating patients 
with early esophageal cancers such as squamous cell 
carcinoma and dysplasia of Barrett’s esophagus. How-
ever, the large defects in the esophageal mucosa often 
cause severe esophageal strictures, which dramatically 
reduce the patient’s quality of life. Although preventive 
endoscopic balloon dilatation can reduce dysphagia 
and the frequency of dilatation, other approaches are 
necessary to prevent esophageal strictures after ESD. 
This review describes several strategies for prevent-
ing esophageal strictures after ESD, with a particular 
focus on anti-inflammatory and tissue engineering ap-
proaches. The local injection of triamcinolone acetonide 
and other systemic steroid therapies are frequently 
used to prevent esophageal strictures after ESD. Tis-
sue engineering approaches for preventing esophageal 
strictures have recently been applied in basic research 
studies. Scaffolds with temporary stents have been ap-
plied in five cases, and this technique has been shown 
to be safe and is anticipated to prevent esophageal 
strictures. Fabricated autologous oral mucosal epithelial 
cell sheets to cover the defective mucosa similarly to 
how commercially available skin products fabricated 
from epidermal cells are used for skin defects or in 
WJG 20th Anniversary Special Issues (13): Gastrointestinal endoscopy
TOPIC HIGHLIGHT
15098 November 7, 2014|Volume 20|Issue 41|WJG|www.wjgnet.com
therapy. Moreover, the use of  endoscopic balloon dilata-
tion (EBD) to treat esophageal strictures carries the risk 
of  perforation. Takahashi et al[29] reported that esophageal 
perforations were observed in 7 of  76 patients who re-
ceived EBD for the treatment of  esophageal strictures. 
The occurrence of  strictures after esophageal ESD is 
more common in EBD performed after esophageal stric-
tures (92%) than in multiple sessions of  EBD performed 
weekly before esophageal strictures (59%)[30]. Further-
more, the duration of  EBD after esophageal stricture is 
generally shorter in patients who undergo multiple ses-
sions of  EBD before developing esophageal strictures 
(29 d) than in those who undergo EBD after esophageal 
strictures form (78 d). Although multiple sessions of  
EBD before esophageal strictures can prevent esophageal 
strictures after ESD, such frequent dilatation treatments 
are problematic because of  their high invasiveness and 
cost. Therefore, less invasive approaches are desired. 
Various approaches have been used to prevent esopha-
geal strictures after ESD and can be generally categorized 
as either anti-inflammatory drugs or tissue engineering 
technologies. 
ANTI-INFLAMMATORY APPROACHES 
Anti-inflammatory approaches for preventing esophageal 
strictures after ESD are based on the concept that subse-
quent strictures may be suppressed by inhibiting the infil-
tration of  inflammatory cells, the hyperplasia of  granula-
tion, and the fibrosis of  the remaining submucosal layer 
at the ulcer site. Anti-inflammatory treatments using 
steroids have recently been demonstrated to prevent 
esophageal strictures after ESD (Table 1). Basic research 
has also been conducted on several potential drugs that 
selectively inhibit fibrotic formation.
Endoscopic intralesional injections of steroids
Endoscopic intralesional injections of  steroids are applied 
based on the concept that inflammation and fibrosis after 
esophageal ESD are inhibited by the direct administration 
of  steroids to the ulcer site. The initial reports regarding 
steroid therapy demonstrated that intralesional injections 
of  triamcinolone acetonide after the dilatation of  benign 
esophageal strictures reduces the frequency of  esopha-
geal strictures in the endoscopic field[31,32]. These results 
are similar to findings for the injection of  triamcinolone 
acetonide to treat keloid scars[31,33,34]. Subsequently, triam-
cinolone acetonide has been used to prevent esophageal 
strictures after ESD (Table 2). Hashimoto et al[35] reported 
that the local injection of  triamcinolone acetonide into 
the ulcer site prevents esophageal strictures after ESD. 
Twenty-one patients were treated with local injections of  
triamcinolone acetonide at 3, 7, and 10 d after ESD. The 
total dose of  triamcinolone acetonide was 18 to 62 mg in 
each injection session. The stricture rate in the patients 
who were given the local injection (19%, 4/21) was lower 
than in the control patients (75%, 15/20) (P = 0.03). 
Furthermore, the frequencies of  dilatation in the patients 
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cases of intractable ulcers. Fabricated autologous oral-
mucosal-epithelial cell sheets have already been shown 
to be safe. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Esophageal strictures after extensive endo-
scopic submucosal dissection (ESD) reduce quality of 
life. Endoscopic local injections and the oral adminis-
tration of steroids are safe and effective for prevent-
ing esophageal strictures. In addition, several tissue 
engineering therapies have been used in attempts to 
overcome severe esophageal strictures. Cell-based tis-
sue engineering therapy with fabricated autologous oral 
mucosal epithelial cell sheets has been used to prevent 
esophageal strictures after ESD in nine patients. This 
therapy has been shown to be safe and may be widely 
used in the future.
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INTRODUCTION
Endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) are accepted as less invasive 
treatments for early esophageal cancers, including squa-
mous cell carcinoma and dysplasia of  Barrett’s esophagus 
(BE)[1-17]. Additionally, radiofrequency ablation has been 
shown to be safe and effective for treating patients with 
dysplasia due to BE[18-24].
The occurrence of  severe esophageal strictures af-
ter endoscopic treatments for large tumors remains an 
unsolved problem. However, the safety and efficacy of  
endoscopic treatments have been technically and oncolog-
ically established for a wide range of  esophageal intramu-
cosal neoplasms and BE. Risk factors for esophageal stric-
tures after ESD include the cervical location, a tumor size 
greater than 3/4 of  the esophageal circumference, and a 
longitudinal tumor diameter of  more than 40 mm[9,25-27]. 
Furthermore, esophageal strictures after the treatment of  
BE are often observed at the resection site with at least 
50% of  the esophageal mucosal circumference[28]. 
Esophageal strictures cause dysphagia, and patients 
are required to receive repeated balloon dilatation pro-
cedures or temporary stents. These esophageal stric-
tures decrease the patient’s quality of  life, although the 
endoscopic treatment itself  is less invasive than surgical 
who were given a local injection (mean 1.7, range 0-15) 
were significantly lower than the frequency of  control 
patients (mean 6.6, range 0-20) (P > 0.001). Hanaoka et 
al[36] also reported that local injection of  triamcinolone 
prevented esophageal strictures after ESD using a single 
injection of  triamcinolone acetonide immediately after 
ESD. The total dose of  triamcinolone acetonide was 
100 mg[36]. In Nagasaki University Hospital, 3/4-circum-
ferential ESD cases are generally treated with this local 
injection therapy. Fifty mg of  triamcinolone acetonide is 
endoscopically injected in submucosal layer 1 or 2 times 
for 3 wk and generally results in a satisfactory outcome. 
It is recommended that triamcinolone acetonide doses 
of  approximately 18 to 100 mg are injected several times 
into the ulcer site in the early phase after ESD to prevent 
esophageal strictures. However, triamcinolone injection 
might be insufficient to prevent esophageal strictures for 
large mucosal defects because esophageal strictures can 
develop after the combinational treatments of  dilata-
tion and triamcinolone injection for benign esophageal 
strictures[31,32,37]. The patients with circumferential ESD 
were excluded in the clinical studies of  local injections 
of  triamcinolone[35,36]. There is also a high risk of  ulcer 
formation due to endoscopic local injection when the 
muscularis is missed during the injection[38]. Additionally, 
insufficient fibrosis causes the ulcer site of  the esopha-
geal wall to be fragile and leads to perforation after bal-
loon dilatation. Isomoto et al[27] developed a special injec-
tion needle for injecting ulcer sites after ESD. The needle, 
which is 25 gauge with a length of  1.8 mm, is finer and 
shorter than conventional injection needles, which are 
usually 23 or 25 gauge in diameter and 4 mm in length, 
thereby avoiding deep injections into the muscularis. 
Systemic steroid therapy for preventing esophageal 
strictures after ESD
The efficacy of  systemic steroid therapy for preventing 
esophageal strictures after ESD has been confirmed by 
Yamaguchi et al[39]. In their study, 22 patients who under-
went multiple sessions of  EBD before esophageal stric-
tures were compared with 19 patients who underwent 
systemic steroid therapy. The stricture rate in the systemic 
steroid therapy group (5.3%, 1/19) was significantly 
lower than that in the multiple sessions of  EBD before 
esophageal strictures group (31.8%, 7/22) (P < 0.0001). 
Furthermore, the frequency of  dilatation in the systemic 
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Table 1  Anti-inflammatory drugs for the prevention of esophageal strictures after endoscopic submucosal dissection
Action Administration Advantages Disadvantages and limitations
Clinical study
   Corticosteroids Steroidal Oral intake Strongly inhibits the infiltration of inflammatory 
cells, the hyperplasia associated with 
granulation, and the fibrosis of the remaining 
submucosal layer
General side effects 
(severe infection, peptic ulcer, hyperglycemia, 
psychiatric symptoms, and osteoporosis) 
 Delayed wound healing
   Triamcinolone 
   acetonide
Steroidal Local injection Inhibits the infiltration of inflammatory cells, the 
hyperplasia associated with granulation, and the 
fibrosis of the remaining submucosal layer
Risk of ulcer formation due to accidental 
injection into the muscularis
Delayed wound healing 
Pre-clinical study
   MMC Inhibition 
of DNA 
synthesis 
Local injection Inhibits the proliferation and activation of 
fibroblasts 
An effect has not been shown for the prevention 
of esophageal strictures, although MMC 
improves recurrent dysphagia or restenosis after 
the dilatation of esophageal strictures
The risks of perforation and secondary 
malignancy
   N-acetylcysteine Antioxidant 
molecule
Oral intake Antifibrotic effect without the inhibition of 
wound healing
Insufficient effect in an animal model of severe 
esophageal stricture
MMC: Mitomycin C.
Table 2  Intraregional triamcinolone injection for preventing esophageal strictures after endoscopic submucosal dissection 























Hashimoto et al[35] > 3/4 54 25 G, 
4 mm
10 0.2   9-31 18-62 Three 
times2
19% 1.7 (0-15) 1 yr
(28-60)  (4/21)
Hanaoka et al[36] > 3/4 58 ± 11 25 G   5 0.5-1 20-40 100 Single3 6.60% 0 (0-2) 2 mo
(3/30)
1The cases of whole circumferential endoscopic submucosal dissection (ESD) are excluded; 2Three sessions of locoregional triamcinolone injection are per-
formed at 3, 7, 10 d after ESD; 3Only single session of locoregional triamcinolone injection is performed immediately after ESD. G: Gaze; EBD: Endoscopic 
balloon dilatation.
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sive ESD, systemic administration of  steroids might not 
prevent esophageal strictures after a very long segmental 
circumferential ESD. This occurs because systemic ste-
roid therapy does not prevent esophageal strictures after 
major injuries of  the esophagus involving a long length 
of  circumferential mucosal defect[41,42].
Potential drugs to target fibrotic formation
There are several studies regarding specifically preventing 
excessive fibrotic formation to avoid the various adverse 
effects of  steroid therapies. The locoregional injection of  
mitomycin C into the esophageal stricture after ESD was 
shown to improve recurrent dysphagia or restenosis with-
out serious complications in 5 patients[43]. Mitomycin C is 
also effective for the treatment of  refractory esophageal 
strictures which include caustic, surgical, and peptic stric-
tures[44]. Additionally, because mitomycin C injection has 
an anti-proliferative effect on fibroblasts it also prevents 
refractory esophageal strictures. Although the injection 
of  mitomycin C is suggested for preventing esophageal 
strictures after ESD, it has poor reproducibility in an 
animal model[45]. Mitomycin C might cause several local 
adverse events such as delayed mucosal healing, ulcer 
formation, and perforation. In long-term studies, second-
ary malignancy should be examined because mitomycin 
induces DNA damage[46,47].
N-acetylcysteine is an antioxidant compound with an-
tifibrotic effects that is also expected to prevent esopha-
geal strictures. However, its efficacy is minimal in animal 
models of  severe esophageal strictures after ESD[48]. 
steroid therapy group (mean 1.7, range 0-7) was signifi-
cantly lower than in the multiple sessions of  EBD before 
esophageal strictures group (mean 15.6, range 0-48) (P 
< 0.0001). Sato et al[40] reported that systemic steroid 
therapy with EBD is also more effective than EBD alone 
in preventing esophageal strictures after circumferential 
ESD. In Nagasaki University Hospital, patients who have 
at least two of  the following risk factors are treated with 
systemic steroid therapy after esophageal ESD: more 
than 3/4-circumferential ESD, a longitudinal tumor di-
ameter greater than 40 mm, and cervical location. Begin-
ning 2 d after ESD, 0.5 mg/kg prednisolone per day was 
administered orally for 2 wk. The dose of  prednisolone 
was continuously reduced until the regenerative mucosa 
covered the artificial ulcer site of  the esophageal ESD 
(Figure 1). However, complete healing of  the esophageal 
mucosa generally requires 8-16 wk because steroids in-
hibit the activation of  fibroblasts and inflammatory cells 
and reduce the proliferation and migration of  epithelial 
cells. High doses of  prednisolone have been associated 
with the possibility of  developing adverse effects such as 
severe infections, peptic ulcers, hyperglycemia, psychiatric 
symptoms, and osteoporosis. However, no adverse events 
occurred in the clinical studies of  systemic steroid ther-
apy for preventing esophageal strictures after ESD[27,39]. 
Furthermore, the perforation risk of  balloon dilatation 
after steroid therapy by either local injection or systemic 
administration may be higher than in multiple sessions 
of  EBD treatment[38]. Although systemic administration 
of  steroids prevents esophageal strictures after exten-
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Figure 1  Systemic steroid therapy for the prevention of esophageal strictures after endoscopic submucosal dissection[83]. A 72-year-old man underwent 
esophageal endoscopic submucosal dissection (ESD) for early squamous cell carcinoma. Systemic steroid therapy with prednisolone was started at postoperative day 
2. At postoperative day 51 following esophageal ESD, the ulcer surface was covered with a regenerative mucosa, and no esophageal stricture was present. Figures 
are reproduced courtesy of Shindan to Chiryo Sha, Inc. POD: Postoperative day.
POD 0 POD 7 POD 56
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N-acetylcysteine has been clearly shown to promote 
corneal wound healing better than steroid therapy. Thus, 
combination therapy involving N-acetylcysteine and 
other treatments may potentially be effective[49]. 
TISSUE ENGINEERING APPROACHES
Tissue engineering approaches for preventing esopha-
geal strictures after ESD are based on the concept that 
transplanted materials and tissues can repair and replace 
damaged tissues, maintain the physiological functions of  
these tissues, and enhance mucosal healing. This issue is 
especially important because mucosal defects cause se-
vere inflammation at artificial ulcer sites. Tissue engineer-
ing approaches for preventing esophageal strictures after 
ESD are divided into two groups: scaffold-based therapy 
and cell-based therapy. 
Scaffold-based therapies
Temporary scaffolds made from biodegradable materials 
can support tissue and protect esophageal strictures. Saito 
et al[50] reported that biodegradable stents composed of  
poly-L-lactic acid prevented esophageal strictures after 
ESD in 2 patients. Additionally, Nieponice and Badylak 
reported that an extracellular matrix (ECM) biologic scaf-
fold composed of  porcine-derived small intestinal sub-
mucosa, together with a temporary metallic stent, is safe 
and efficacious for the prevention of  esophageal stric-
tures after endoscopic resection in animal models[51-53]. 
Biological scaffolds have been safely used to treat five 
high-grade BE patients undergoing endoscopic resec-
tion[54]. Long length (8 to 13 cm) circumferential resec-
tions were performed in these patients. The esophageal 
strictures after endoscopic resection and were improved 
by only a few sessions (0 to 9) of  endoscopic dilatation 
even though the temporary stent support prevented 
strictures. Surprisingly, the small perforation site healed 
in 18 d by covering the perforation with a biological scaf-
fold and stent. The scaffold provides an ECM, supports 
strictures, and promotes cell migration. However, it may 
be insufficient to cover an extensive mucosal defect after 
esophageal ESD. The acellular scaffold of  the esophageal 
mucosa includes key proteins required for producing 
a basal membrane. Additionally, the acellular scaffold 
of  the esophageal mucosa provides a suitable environ-
ment that facilitates cell adhesion and proliferation[55]. 
Consequently, the risk of  local recurrence after scaffold 
transplantation may be higher than at normal ulcer sites 
because the scaffold itself  is also a good environment 
for the engraftment of  unwelcome malignant cells. The 
transplantation of  biomaterials is also associated with the 
risk of  developing a local infection, which affects the mi-
croenvironment of  wound healing. This issue is especially 
important for esophageal mucosal healing because both 
the esophageal lumen and the oral cavity are constantly 
exposed to microorganisms. Scaffold-based therapies cur-
rently lack sufficient clinical evidence that prevent their 
use for esophageal strictures and have potential risks of  
adverse events such as a local recurrence and infection. 
In the future, the development of  novel materials and the 
advancement of  biological science will help solve these 
problems. 
Cell-based therapies
Cell-based therapies are expected to have trophic effects 
on the host as the transplanted cells release cytokines 
and growth factors and interact with other host cells. 
The direct injection of  primary cells into the host organ 
has two major disadvantages, which are low viability and 
quick diffusion from the host sites after transplantation. 
Transplanted cells are difficult to engraft at the target site. 
As a result, there have been several in vitro attempts to 
engineer tissues with the ability to effectively engraft cells 
at the target site. 
Technology of autologous oral mucosal epithelial cell 
sheets
In our laboratory, epithelial cell sheets of  oral mucosa 
without any scaffold are fabricated on temperature-
responsive culture inserts that are grafted with poly-N-
isopropylacrylamide (PIPPAm)[56]. At 37 ℃, PIPPAm be-
comes hydrophobic, but below its lower critical solution 
temperature of  32 ℃ it is hydrophilic[57,58]. Cells attach 
and proliferate on the hydrophobic surface of  the cell 
culture insert at 37 ℃. However, due to the remarkable 
character of  PIPPAm, the cells can detach themselves 
from the surface when the temperature is below 32 ℃ 
and PIPPAm becomes hydrophilic. This behavior en-
ables the cell sheets to be harvested without the use of  
enzymes and allows the cells to preserve their cell-mem-
brane proteins and cell-to-cell junctions. Subsequently, 
the fabricated epithelial cell sheets can be grafted to the 
host organ without any adhesive materials because the 
ECM is deposited on the basal layer of  the epithelial cell 
sheets and the basal side can attach to the artificial ulcer 
site[59]. Furthermore, the transplantation of  autologous 
oral epithelial cell sheets to an esophageal mucosal de-
fect has been shown to promote re-epithelization of  the 
esophageal mucosa in a canine model[60]. 
Preparing autologous oral mucosal epithelial cell sheets 
for clinical application
For clinical applications, oral mucosal epithelial cell 
sheets must be fabricated in a cell processing center (CPC) 
(Figure 2)[61,62]. CPCs have separate clean rooms that meet 
good manufacturing practice guidelines, and various other 
parameters (such as aerosol, temperature, and humidity) 
are monitored to validate the clean environment of  the 
CPC. To prevent possible human errors and careless mis-
takes during the fabrication of  oral mucosal epithelial cell 
sheets, standard operation procedures (SOPs) for culture 
methods are documented and a second person always 
checks the document while the first operator performs 
the procedure in the CPC. In addition, to ensure safety 
and avoid possible immune reactions and unknown infec-
tions animal-derived materials are eliminated as much as 
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Figure 2  Protocol for the fabrication of autologous oral epithelial cell sheets for clinical application. Autologous oral epithelial cell sheets are fabricated using 
autologous serum and oral mucosa in the cell processing center (CPC). Isolated oral epithelial cells are cultured on a temperature-responsive membrane for 16 d. The 
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possible. In our clinical study, autologous serum is used 
instead of  fetal bovine serum, which is commonly used 
for culturing cells[61]. 3T3 feeder cells are fibroblast cells 
obtained from mice. These cells are classified as a xeno-
geneic material by the Food and Drug Administration in 
the United States and have never been used for culture 
in our system. However, these feeder cells are known to 
promote the proliferation of  various epithelial cells[63]. 
The fabricated oral mucosal epithelial cell sheets are re-
quired to pass all validation tests including a sterility test, 
a harvesting test, and a purity test prior to transplanta-
tion[64]. However, no tests for cell proliferation, migration, 
and attachment are included. In the future, noninvasive 
measurements of  these test parameters will be required 
prior to clinical application. 
Transplanting autologous oral epithelial mucosal cell 
sheets into artificial ulcer sites after ESD
Before transplantation of  the autologous mucosal epi-
thelial cell sheet into the artificial ulcer site after esopha-
geal ESD, an esophageal endoscopic mucosal resection 
(EEMR) tube (Create Medic, Tokyo, Japan) is inserted 
into the patient’s esophagus. The endoscopic transplanta-
tion of  the autologous oral mucosal epithelial cell sheet 
is immediately performed after esophageal ESD using a 
support membrane and endoscopic forceps. The trans-
planted autologous oral mucosal epithelial cell sheets 
adhere to the ulcer site within a few minutes without 
suturing or any adhesive materials because the cell sheets 
maintain adhesive proteins on their basal side and have 
cell-to-cell junctions. The fabricated autologous oral mu-
cosal epithelial cell sheet is composed of  a basal layer and 
an apical layer. The basal layer is gently attached to the 
ulcer site and this procedure requires careful handling. 
The transplant can be disturbed by spasm of  the mus-
cularis and by the entry balloon of  the EEMR tube used 
to maintain the intraluminal pressure of  the esophagus. 
Therefore, a device that facilitates transplantation of  the 
autologous mucosal epithelial cell sheets into the ulcer 
site after esophageal ESD is needed. 
Clinical study using autologous oral mucosal epithelial 
cell sheets
The safety of  transplanting autologous oral mucosal 
epithelial cell sheets into artificial ulcer sites has been 
demonstrated in a phase Ⅰ study[65]. The transplantation 
of  oral mucosal epithelial cell sheets prevented esopha-
geal strictures after ESD in 8 of  9 cases. In the eight suc-
cessful cases, there was no dysphagia and strictures after 
esophageal ESD and no additional treatments for com-
plications were required. Only one cases required balloon 
dilatation of  the esophageal stricture after ESD. Addi-
tionally, mucosal healing was rapidly completed within 3 
to 5 wk. This observation suggests that autologous oral 
epithelial cell sheets promote epithelial healing and result 
in the satisfactory prevention of  esophageal strictures 
after ESD (Figure 3). In the future, a large study must be 
performed to confirm that autologous oral mucosal epi-
thelial cell sheets are an effective material for the preven-
tion of  esophageal strictures after ESD. 
Future topics for standardizing treatments using 
epithelial cell sheets 
Cell-based therapy using autologous oral mucosal epi-
thelial cell sheets has several disadvantages compared 
with scaffold-based therapy and anti-inflammatory drug 
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Figure 3  Transplantation of autologous oral epithelial cell sheets for the prevention of esophageal strictures after endoscopic submucosal dissection[65]. 
A 55-year-old man underwent esophageal endoscopic submucosal dissection (ESD) for early squamous cell carcinoma. Seven fabricated autologous oral epithelial 
cell sheets were transplanted immediately after esophageal ESD. At postoperative day 21, the ulcer surface after esophageal ESD was covered with a regenerative 
mucosa, and no esophageal stricture was present. Figures are reproduced courtesy of Elsevier. POD: Postoperative day.
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therapy. First, a CPC is necessary to culture the oral epi-
thelial cells. Thus, the operating cost is high and is cur-
rently estimated to be at least 20000 to 30000 USD per 
case. Thus, fabricating oral mucosal epithelial cell sheets 
in a CPC in every hospital will be technically and finan-
cially difficult. One alternative is ready-made oral mucosal 
epithelial cell sheets that can be transported in a suitable 
environment from a production site to the hospital where 
the transplantation will be performed. Second, the fab-
rication of  autologous oral mucosal epithelial cell sheets 
requires the patient’s own tissues and serum. Although 
autologous oral epithelial cell sheets have been success-
fully fabricated, it is difficult to maintain consistent fabri-
cation quality and quantity because individual differences 
can affect cell proliferation and differentiation. Third, 
possible bacterial and fungal contamination during the 
culture of  oral mucosal epithelial cell sheets is the most 
common factor leading to failure, which may be a disap-
pointment to patients who have provided their own tis-
sues. Fourth, multiple neoplasms in the oral and throat 
areas are sometimes observed in patients with esophageal 
cancer so harvesting tissues from the premalignant re-
gion in the oral mucosa must also be avoided because the 
transplantation of  multipotent cancer cells may cause lo-
cal recurrence[66,67]. Translational research studies aimed at 
improving these disadvantages are currently in progress 
in our laboratory. 
Epidermal cells are expected to be suitable substitutes 
for oral mucosal epithelial cells. Epidermal cells have 
characteristics similar to esophageal and oral mucosal epi-
thelial cells because these cells are classified as squamous 
cells. Furthermore, epidermal cells are frequently cultured 
for the production of  cutaneous medical devices that are 
already used in clinics[68-72]. The risk of  contamination 
with malignant cells is lower in the skin than in the oral 
mucosa, and the epidermis is composed of  keratinocytes. 
Additionally, in a swine model, cell sheets made from 
autologous epidermal cells have been shown to prevent 
esophageal strictures after ESD as effectively as oral mu-
cosal epithelial cell sheets[73]. 
The capability of  fabricating cell sheets in serum-
free medium is essential to reduce the variation between 
individual differences and to standardize cell culture 
procedures. Specifically, the addition of  an IL-1 receptor 
antagonist has been found to be beneficial for fabricating 
cell sheets in serum-free medium[74]. 
Adipose-derived stem cells
Adipose-derived stem cells (ADSCs) are similar to bone 
marrow-derived stem cells. ADSCs have the following 
biological features: growth factor secretion, capacity to 
differentiate into multiple cell types, ability to suppress in-
flammatory cells, ability to promote angiogenesis and en-
hanced of  wound healing[75-77]. Additionally, ADSCs can 
be obtained easily from adipose tissue. Cell therapies us-
ing ADSCs have been performed to repair bone defects, 
treat complex perianal fistulas in Crohn’s disease, and 
alleviate severe steroid-resistant graft-vs-host disease[78-80]. 
Cell-based therapy using ADSCs is also expected to pre-
vent esophageal strictures after ESD. The local injection 
of  autologous ADSCs after esophageal EMR has also 
been found to prevent esophageal strictures in a canine 
model[81]. This result is insufficient evidence for conclud-
ing that ADSCs prevent esophageal strictures after ESD 
because no evaluations of  the surface markers, multipo-
tentiality, and proliferation of  the injected cells have been 
performed. 
Future prospects of treatments using tissue engineering 
for esophageal stricture therapy 
Tissue engineering approaches have great potential for 
treating various damaged tissues and organs. Currently, 
treatments using tissue engineering must include safety 
and quality controls and require careful observations after 
transplantation. Esophageal tissue engineering will be de-
veloped and become available in the near future because 
transplanted engineered tissues can be noninvasively ob-
served by endoscopy and because unexpected complica-
tions such as local infections, immunological responses, 
and tumorigenesis are easily managed. 
The replacement of  mucosal structures with a basal 
membrane after esophageal ESD may be a novel tissue 
engineering therapy for the prevention of  esophageal 
strictures after ESD. Therefore, sufficient numbers of  
cells and biomaterials in basal membranes are necessary 
to overcome severe esophageal strictures after ESD.
Tissue engineering approaches will also provide a 
treatment for refractory esophageal strictures. Patch 
esophagoplasty using biologic scaffolds for refractory 
esophageal strictures has already been performed in 4 pa-
tients[82]. Various treatments using tissue engineering for 
refractory esophageal strictures will be performed in the 
near future. 
CONCLUSION
This review reports several strategies for preventing 
esophageal strictures after extensive ESD with a focus on 
anti-inflammatory, scaffold-based, and cell-based treat-
ments. Anti-inflammatory treatments, which are mainly 
local and systemic steroid therapies, have shown positive 
outcomes in small comparative clinical studies. However, 
the clinical evidence of  scaffold-based and cell-based 
treatments is still insufficient, and their efficacy needs to 
be confirmed in comparative studies because they are po-
tentially new technologies for tissue engineering and nov-
el treatment strategies for wound healing. To establish a 
truly minimally invasive treatment using endoscopic sur-
gery, improvements to all of  these methods are needed. 
Nonetheless, these three strategies will eventually become 
available as a combined therapy in the future. 
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